Abstract
Abatacept is the first in a new class of agents for the treatment of rheumatoid arthritis. We report a case of guttate psoriasis in a patient treated with abatacept for rheumatoid arthritis. This patient had the same reaction with etanercept in the past.
MeSH terms
-
Abatacept
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use
-
Antirheumatic Agents / adverse effects
-
Antirheumatic Agents / therapeutic use
-
Arthritis, Rheumatoid / drug therapy
-
Etanercept
-
Female
-
Humans
-
Immunoconjugates / adverse effects*
-
Immunoconjugates / therapeutic use
-
Immunoglobulin G / adverse effects*
-
Immunoglobulin G / therapeutic use
-
Methotrexate / therapeutic use
-
Middle Aged
-
Psoriasis / chemically induced*
-
Psoriasis / diagnosis
-
Psoriasis / drug therapy
-
Psoriasis / pathology
-
Receptors, Tumor Necrosis Factor / therapeutic use
-
Rituximab
-
Steroids / therapeutic use
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Antirheumatic Agents
-
Immunoconjugates
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Steroids
-
Rituximab
-
Abatacept
-
Etanercept
-
Methotrexate